Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P7HQ
|
|||
| Drug Name |
Pyrazole derivative 13
|
|||
| Synonyms |
PMID26161824-Compound-25
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H17Cl2F3N8O
|
|||
| Canonical SMILES |
C1=CC(=C(N=C1)N2C(=C(C(=N2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F)CC4=NNN=N4)C5=CC=C(C=C5)Cl)Cl
|
|||
| InChI |
1S/C25H17Cl2F3N8O/c26-17-9-5-15(6-10-17)22-18(12-20-33-36-37-34-20)21(35-38(22)23-19(27)2-1-11-31-23)24(39)32-13-14-3-7-16(8-4-14)25(28,29)30/h1-11H,12-13H2,(H,32,39)(H,33,34,36,37)
|
|||
| InChIKey |
FXZYLULQTVQTLV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.